Roch Houot
Roch Houot, MD, PhD is an expert in Hematology at Centre Hospitalier Universitaire de Rennes (France). As of October 2026, ScienceLeadR ranks Roch Houot in the top 1% of experts worldwide for Lymphoma and Lymphoproliferative Disorders. Roch Houot has authored 468 publications, the most recent in 2026, and is an investigator in 61 clinical trials, 27 of them ongoing. SLR score: 2,711 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
www.linkedin.com/in/roch-houot-3b18348
Organizations
Career arc: 2005 - 2026
Number : 468
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: a DESCAR-T study. PMID 42501071 — cells, lymphoma, lymphoma, large b-cell, diffuse, positron emission tomography computed tomography, nuclear medicine, therapeutics, t-lymphocytes, car-t cell | Eur J Nucl Med Mol Imaging | 2026 | 0 |
| Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis. PMID 42774885 — cells, lymphoma, b-cell, lymphoma, b-lymphocytes, transplantation | Hemasphere | 2026 | 0 |
| Outcomes of refractory and early-relapsed large B-cell lymphoma patients after first-line treatment in the prospective Real-world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre-CAR T era. PMID 42669939 — cells, hematology, lymphoma, b-cell, lymphoma, therapeutics, b-lymphocytes | Br J Haematol | 2026 | 0 |
| Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. PMID 42629429 — registries, cells, lymphoma, b-cell, lymphoma, bone marrow transplantation, therapeutics, t-lymphocytes, b-lymphocytes, car-t cell | Bone Marrow Transplant | 2026 | 0 |
| Nutritional outcomes associated with enteral versus parenteral nutritional support during intensive induction chemotherapy for acute myeloid leukemia. PMID 42613390 — nutritional support, malnutrition, induction chemotherapy, leukemia, drug therapy, leukemia, myeloid, acute, parenteral nutrition, leukemia, myeloid, weight loss, therapeutics, palliative care, enteral nutrition, chemotherapy | Support Care Cancer | 2026 | 0 |
Clinical Studies 61
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
27 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Phase 1 Study of CD19 targeted NEX T CAR T Cells in Participants with Severe Refractory Autoimmune Diseases (Breakfree 1) 2023-503823-24-01 — cells, autoimmune diseases, car-t cell | Phase 1 | Active not recruiting | 2024 |
| CAR T cell treatment for untreated high risk MANtle Cell Lymphoma 2022-502405-15-01 — cells, lymphoma, maintenance, rituximab, lymphoma, mantle-cell, therapeutics, t-lymphocytes, car-t cell | Phase 2 | Recruiting | 2024 |
| A Study to Understand the Optimization of the Cytokine Release Syndrome Profile for Glofitamab along with Gemcitabine Plus Oxaliplatin in Patients with Relapsed Refractory Aggressive B Cell Non Hodgkin s Lymphoma 2024-516791-15-00 — cytokines, cells, hodgkin disease, lymphoma, oxaliplatin, cytokine release syndrome, lymphoma, non-hodgkin, b-lymphocytes | Phase 2 | Active not recruiting | 2025 |
| A Study to Evaluate Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Lenalidomide in Patients with Follicular Lymphoma 2023-505807-21-00 — lymphoma, follicular, safety, lymphoma, rituximab, lenalidomide, therapeutics | Phase 3 | Active not recruiting | 2021 |
| A phase II multicenter open label study evaluating Glofitamab in combination with Venetoclax plus Zanubrutinib or Venetoclax alone in subjects with untreated or relapsed refractory high risk mantle cell lymphoma 2023-506706-40-00 — cells, lymphoma, maintenance, lymphoma, mantle-cell | Phase 2/Phase 3 | Recruiting | 2025 |
LeadR Networks
Main global connection map